2022 / 05

DOI: 10.24075/brsmu.2022.054

ORIGINAL RESEARCH

The nature of genotypic resistance to fluoroquinolones in Mycobacterium tuberculosis circulating in Russian Federation

Andreevskaya SN, Smirnova TG, Chernousova LN, Larionova EE, Kiseleva EA, Ergeshov A
About authors

Central Tuberculosis Research Institute, Moscow, Russia

Correspondence should be addressed: Sofia N. Andreevskaya
Yauzskaya Alleya, 2, str. 1А, Moscow, 107564, Russia; ur.liam@aifosdna

About paper

Funding: the study was conducted as part of the State Assignment № 122041100246-3 for the Central Tuberculosis Research Institute, “Intra- and Inter- species Polymorphism of Mycobacteria in Patients with Tuberculosis and Mycobacteriosis Who Receive Specific Therapy”.

Author contribution: Ergeshov A, Chernousova LN — study design; Larionova EE, Kiseleva EA — data acquisition; Smirnova TG — data analysis; Andreevskaya SN — manuscript writing, literature review; all authors contributed to the discussion.

Received: 2022-10-10 Accepted: 2022-10-24 Published online: 2022-10-31
|
Table 1. Frequency of single gyrA mutations in the total number of strains with mutations in gyrA (n = 699)
Table 2. MTB isolates with various gyrA QRDR structure showing phenotypic resistance to levofloxacin (nn = 1326)
Note: WT — wild type gyrA; * — only MTB isolates with known phenotypic resistance to fluoroquinolones are taken into account.
Table 3. Abundance of the gyrA mutant MTB variants in the groups of the new cases and retreatment cases with tuberculosis
Note: NC — new cases; RC — retreatment cases.
Table 4. MTB isolates with various resistance profiles and various structure of gyrA*
Note: MDR — multiple drug resistance; Poly — polyresistance; Mono — monoresistance; FQ — fluoroquinolones; ATBD — antituberculosis drugs; sens — sensitive to ATBD; WT — wild type gyrA; * — only samples with known resistance type were included in the analysis.
Table 5. Heteroresistance to fluoroquinolones
Note: NC — new cases; RC — retreatment cases; ATBD — antituberculosis drugs; FQ — fluoroquinolones; MDR — multiple drug resistance; Poly — polyresistance; Mono — monoresistance; N/d — no data available; WT — wild type gyrA; * — cases of the detected double gyrA mutation are included.